Influenza outbreak

RECENT NEWS
NPR  Sep 24  Comment 
Scientists are deeply divided on whether lab-made flu viruses are legitimate medical research or national security threats. A new federal policy asks institutions to evaluate those risks early on.
Benzinga  Sep 23  Comment 
Vaccine and adjuvant were well-tolerated, consistent with the company's prior studies with saponin-based adjuvants  Hemagglutination-inhibiting antibody responses similar to prior Novavax studies of A(H7N9) with another saponin...
DailyFinance  Sep 16  Comment 
YONKERS, NY -- (Marketwired) -- 09/16/14 -- ContraFect Corporation (NASDAQ: CFRX) (NASDAQ: CFRXW) (NASDAQ: CFRXZ), a biotechnology company focused on the discovery and development of protein therapeutics and antibody products for...
GenEng News  Sep 12  Comment 
Influenza can increase the risk of complications for sufferers of noncommunicable diseases such as diabetes, heart disease, stroke, and lung diseases. This infographic from IFPMA tells you what you need to know as well as highlights the best way...
MedPage Today  Sep 7  Comment 
WASHINGTON (MedPage Today) -- A single dose of an investigational influenza drug, peramivir (Rapivab), was able to reduce the duration of fever and viral shedding, researchers said here.
Benzinga  Sep 6  Comment 
BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced trial results related to RAPIVAB™ (peramivir injection), a neuraminidase inhibitor (NAI) for the treatment of influenza at the Interscience Conference on Antimicrobial Agents &...
MedPage Today  Sep 5  Comment 
(MedPage Today) -- Influenza vaccination was immunogenic in pregnant women with and without HIV, researchers reported.
The Hindu Business Line  Sep 2  Comment 
Nearly 18,000 geese died on a poultry farm in northeast China after being stricken by the H5N6 bird flu virus last month, the agriculture ministry said. As many as 20,550 geese on the farm in Harb...
Benzinga  Sep 2  Comment 
BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced the presentation of trial results related to intravenous (I.V.) peramivir for the treatment of influenza at the Interscience Conference on Antimicrobial Agents & Chemotherapy (ICAAC) in...
TechCrunch  Aug 29  Comment 
 Plasticity Labs, a company that uses data analytics to measure workplace morale, announced that it has raised $2.1 million led by Fibernetics Ventures. The funds will be used for sales and development. Plasticity was founded in 2012, three years...




 
TOP CONTRIBUTORS

Influenza, or the flu, is a common infectious disease, which can be deadly to individuals with compromised immune systems (the very young, the very old, and those with conditions such as AIDS or Cancer). However, occasionally particularly virulent strains of influenza break out that can be threatening on a much larger scale -- such as the flu epidemic of 1918 and, more recently, concerns that H5N1 "Bird Flu" or H1N1 "Swine Flu" could mutate into a highly-infectious and deadly virus. A number of pharmaceutical companies make treatments for the flu and benefit from the fear of a flu outbreak.


  • Roche Pharmaceuticals makes Tamiflu, an antiviral pill to treat the flu. In 2005, amid concerns that bird flu might pose a large threat during the winter flu season, many national governments began stocking up on Tamiflu. Chugai pharmaceuticals sells Tamiflu in Japan.
  • Novartis AG (NVS), through its acquisition of Chiron in 2006, supplies much of the traditional flu vaccine supply to the United States.
  • AstraZeneca (AZN), through recently acquired MedImmune, manufactures 'FluMist', a novel flu vaccine that is delivered via an intranasal spray rather than via an injection.

Companies with treatments for H1N1, or "Swine Flu"

In April 2009, a novel flu virus, known as "Swine Flu" because it was believed to have originated in pigs, started infecting humans. By April 28th, there were 1,300 confirmed cases of the flu, known by its scientific designation H1N1, in Mexico, and a handful in the U.S. and other parts of the world.

According to preliminary test done by the US Center for Disease Control, Roche Pharmaceuticals (RHHBY)'s Tamiflu and GlaxoSmithKline (GSK)'s Relenza are active against H1N1, although many older drugs are not. [1]

References

  1. Investors buy up shares of flu drug makers, New York Times, April 27th 2009.
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki